Risk factors for cystic fibrosis related liver disease

Jornal de Pediatria

Volumn 81, Issue 6, 2005, Pages 478-484

  Fagundes, Eleonora D T ^a,b   Roquete, Mariza L V ^a   Penna, Francisco J ^a   Reis, Francisco J C ^a   Goulart, Eugênio M A ^a   Duque, Cristiano G ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UFMG ^*  (Brazil)

Author keywords

Cystic fibrosis; Liver disease; Multivariate analysis

Indexed keywords

URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGE; ARTICLE; ATTENTION; BODY WEIGHT; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENOTYPE; HOSPITAL ADMISSION; HOSPITAL LABORATORY; HOSPITAL SERVICE; HUMAN; INFANT; KAPLAN MEIER METHOD; LIVER DISEASE; MALE; MEDICAL INFORMATION; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PANCREAS INSUFFICIENCY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCORING SYSTEM; SEX; ULTRASOUND; BRAZIL; ONSET AGE; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE;

AGE OF ONSET; BRAZIL; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; LIVER DISEASES; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; SEX FACTORS;

EID: 33645997028     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/jped.1398     Document Type: Article

References (29)

1. Colombo C, Battezzati PM, Strazzabosco M, Podda M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis. 1998;18:227-35.
2. Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid in cystic fibrosis related liver disease: a systematic review. J R Soc Med. 1997;90:6-12.
3. Lindblad A, Glaumann H, Stradvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998;27:166-74.
4. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1999;28 Suppl:S1-13.
5. Colombo C, Apostolo MG, Ferrari M, Seia M, Genoni S, Giunta A, Sereni LP. Analysis of risk for the development of liver disease associated with cystic fibrosis. J Pediatr. 1994;124:393-9.
6. Duthie A, Doherty DG, Williams C, Scott-Jupp R, Warner JO, Tanner MS, et al. Genotype analysis for ΔF508, G551D and R553X mutations in children and young adults with cystic fibrosis with or without liver disease. Hepatology. 1992;15:660-4.
7. Wilschanski M, Rivlin J, Cohen S, Augarten A, Blau H, Aviram M, et al. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics. 1999;103:52-7.
8. Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis. 2001;21:471-88.
9. Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis. Am J Dis Child. 1958;96:6-15.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass. 1958;53:457-81.
11. Campos-Filho N, Franco EL. Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimators. Com Meth Prog Biomed. 1988;27:223-8.
12. Cox DR. Regression models and life-table. J Royal Stat Soc Br. 1972;34:187-220.
13. Fagundes ED, Roquete ML, Penna FJ, Reis FJ, Duque CG. Triagem diagnóstica da hepatopatia da fibrose cística. J Pediatr (Rio J). 2002;78:389-96.
14. Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child. 1995;72:281-4.
15. Ling SC, Wilkinson AS, Hollman AS, McColl J, Evans TJ, Paton JY. The evolution of liver disease in cystic fibrosis. Arch Dis Child. 1999;81:129-32.
16. Williams SM, Goodman R, Thomson A, McHugh K, Lindsell DR. Ultrasound evaluation of liver disease in Cystic Fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol. 2002;57:365-70.
17. Fagundes ED, Silva RA, Roquete ML, Penna FJ, Reis FJ, Goulart EM, et al. Validação do escore ultra-sonográfico de Williams para diagnóstico da hepatopatia da fibrose cística. J Pediatr (Rio J). 2004;80:380-6.
18. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis- therapeutic implications and long term follow up. Arch Dis Child. 1993;68:653-7.
19. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child. 1991;66:698-701.
20. Williams SG, Hayller KM, Hodson ME, Westaby D. Prognosis in cystic fibrosis. N Engl J Med. 1992;327:1244-5.
21. Colombo C, Battezzati PM, Podda M, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology. 1996;23:1484-90.
22. van de Meerberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CH, Vanberge-Henegouwen GP. Low dose versus high dose ursodeoxycholic acid in cystic fibrosis related cholestatic liver disease. Scand J Gastroenterol. 1997;32:369-73.
23. Huang NN, Schidlow DV, Szatrowski TH, Palmer J, Laraya-Cuasay LR, Yeung W, et al. Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis. Am J Med. 1987;82:871-9.
24. Oliveira MC, Reis FJ, Oliveira EA, Colosimo EA, Monteiro AP, Penna FJ. Prognostic factors in cystic fibrosis in a single center in Brazil: a survival analysis. Pediatr Pulmonol. 2002;34:3-10.
25. Wesley A, Dawson K, Hewitt C, Kerr A. Clinical features of individuals with cystic fibrosis in New Zealand. NZ Med J. 1993;106:28-30.
26. Gan KH, Geus WP, Bakker W, Lamers CB, Heijerman HG. Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years. Thorax. 1995;50:1301-4.
27. Gan KH, Veeze HJ, van den Ouweland AM, Halley DJ, Scheffer H, van der Hout A, et al. A cystic fibrosis mutation associated with mild lung disease. N Engl Med. 1995;333:95-9.
28. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol. 1997;145:794-803.
29. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology. 1987;7:1346-58.